Integra Lifesciences Holdings has a Cash Ratio of 1.01. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Integra Lifesciences Holdings's Cash Ratio or its related term are showing as below:
IART'
s Cash Ratio Range Over the Past 10 Years
Min: 0.35 Med: 0.72 Max: 1.51
Current: 1.01
During the past 13 years, Integra Lifesciences Holdings's highest Cash Ratio was 1.51. The lowest was 0.35. And the median was 0.72.
IART's Cash Ratio is ranked worse than 55.15% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 1.23
vs IART: 1.01
Integra Lifesciences Holdings Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Integra Lifesciences Holdings's Cash Ratio
For the Medical Devices subindustry, Integra Lifesciences Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings's Cash Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's Cash Ratio falls into.
Integra Lifesciences Holdings Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings (NAS:IART) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Integra Lifesciences Holdings Cash Ratio Related Terms
Thank you for viewing the detailed overview of Integra Lifesciences Holdings's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Integra Lifesciences Holdings (Integra Lifesciences Holdings) Business Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IART has been successfully added to your 